Details:
Methylnaltrexone bromide is the active ingredient in Relistor®, an FDA-approved prescription medication indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic pain.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
Under the agreement, Purisys will support an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA regarding RCC-33.
Lead Product(s): RCC-33
Therapeutic Area: Oncology Product Name: RCC-33
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: CNBX Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 04, 2021